The frequency of re-surgery after lumbar disc Nucleoplasty in a ten-year period.

Clin Neurol Neurosurg

Department of Neurosurgery, Nova Clinic Biberach, Eichendorffweg 5, 88400, Biberach, Germany; Department of Neurosurgery, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. Electronic address:

Published: July 2018

Objective: Percutaneous disc nucleoplasty (PDN) is a minimally invasive technique. A portion of the nucleus tissue is ablated using the Coblation technique. Re-surgery is an important factor for the clinical outcome. However, the rate of subsequent surgery after PDN is still unknown. The aim of the present study was to investigate the frequency of an additional open surgery after PDN in a retrospective of more than ten years.

Patients And Methods: Retrospective observational study. Consecutive patients who underwent PDN between 2005 and 2006 were included. Patient's satisfaction was evaluated using MacNab's outcome criteria. The patient data (age and gender), the MRI findings (annular fissure or contained herniation) and the follow-up time was evaluated. A distinction was made between patients with only lumbago and patients with radiating pain. The focus of this study was to evaluate the necessity of an additional surgery at the same level. The period of time between the PDN and re-surgery was analyzed.

Results: In total, 203 patients were included in this study. All patients were seen one month after PDN. The follow-up time was longer than five years in 41 patients (20.2%), and longer than 10 years in 16 patients (7.9%). The short-term success rate was 63.5%; however, 18.7% of all patients had to undergo an additional surgery at the index level. Half of these additional surgeries were performed during the first three months after PDN. If only a poor pain reduction was achieved, re-surgery was significantly more frequent compared to patients with substantial pain relief. An initial surgery at the L4-5 level was associated more often with an additional surgery compared to an initial surgery at the L5-S1 level.

Conclusion: The present study is the first study to report the frequency of re-surgery after PDN. At first sight, the fact that 63.5% of patients are satisfied seems to be a good result. However, this short-term result was significantly worsened due to a re-surgery rate at the index level of 18.7%. Moreover, it is possible that nucleoplasty has adverse effects resulting from the puncture and progressive degeneration. Therefore, indications for nucleoplasty should be critically reconsidered.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2018.05.004DOI Listing

Publication Analysis

Top Keywords

additional surgery
12
patients
10
frequency re-surgery
8
disc nucleoplasty
8
pdn
8
surgery pdn
8
follow-up time
8
surgery level
8
longer years
8
years patients
8

Similar Publications

The surgical risk is higher for obese patients undergoing laparoscopic left hemicolectomy. To enhance the surgical safety and efficacy for obese patients, we have innovatively integrated the advantages of various surgical approaches to modify a pancreas-guided C-shaped surgical procedure. The safety and quality were assessed through a retrospective analysis.

View Article and Find Full Text PDF

Background: This study aimed to create a comprehensive Core Outcome Set (COS) for assessing the long-term outcome (≥ 5 years) after Metabolic Bariatric Surgery (MBS), through the use of the Delphi method.

Methods: The study utilized a three-phase approach. In Phase 1, a long list of items was identified through a literature review and expert input, forming the basis for an online Delphi survey.

View Article and Find Full Text PDF

Progress report on multiple endocrine neoplasia type 1.

Fam Cancer

January 2025

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant disorder caused by a germline pathogenic variant in the MEN1 tumor suppressor gene. Patients with MEN1 have a high risk for primary hyperparathyroidism (PHPT) with a penetrance of nearly 100%, pituitary adenomas (PitAd) in 40% of patients, and neuroendocrine neoplasms (NEN) of the pancreas (40% of patients), duodenum, lung, and thymus. Increased MEN1-related mortality is mainly related to duodenal-pancreatic and thymic NEN.

View Article and Find Full Text PDF

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

Objective: This review aims to evaluate the efficacy and safety of premedication comprising mucolytics and/or defoaming agents to improve the quality of visualization during elective upper digestive endoscopy (elective upper GI endoscopy) procedure.

Materials And Methods: A systematic review of the literature contained in electronic databases (Medline/Pubmed, Embase, and Lilacs) was performed to identify randomized controlled trials and systematic reviews that assessed patients undergoing upper gastrointestinal endoscopy (elective upper GI Endoscopy) under sedation, after being premedicated with mucolytics and/or defoaming agents for mucous clearance. A meta-analysis was conducted to determine the relative efficacy and safety profile of such premedication.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!